| Frank K Hixon, MD | |
|
188 Hospital Dr, Suite 101, Fairhope, AL 36532-2043 | |
| (251) 928-0300 | |
| (251) 990-1898 |
| Full Name | Frank K Hixon |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 43 Years |
| Location | 188 Hospital Dr, Fairhope, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285786475 | NPI | - | NPPES |
| 82754 | Other | AL | BLUE CROSS BLUE SHIELD |
| 82754 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 15455 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thomas Hospital | Fairhope, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eastern Shore Ear, Nose And Throat Clinic, Pc | 2769405877 | 4 |
News Archive
Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured venture capital investment of A$12 million from GBS Venture Partners Limited, Brandon Capital Partners and Uniseed to fund the development of its pain management drug, EMA401.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Laboratory studies at Johns Hopkins have revealed that certain products of the enzymes COX-1 and COX-2 can both protect and damage the brain. The findings, published in the February 2005 issue of the Journal of Neurochemistry, offer tantalizing clues to why drugs like Vioxx and Celebrex, which block COX-2, can ease arthritis but potentially harm the heart and brain.
ProPublica offers an examination of the challenges hospitals face in adopting procedures to address medical errors.
› Verified 4 days ago
| Entity Name | Eastern Shore Ear, Nose & Throat Clinic, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386707339 PECOS PAC ID: 2769405877 Enrollment ID: O20060104000374 |
News Archive
Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured venture capital investment of A$12 million from GBS Venture Partners Limited, Brandon Capital Partners and Uniseed to fund the development of its pain management drug, EMA401.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Laboratory studies at Johns Hopkins have revealed that certain products of the enzymes COX-1 and COX-2 can both protect and damage the brain. The findings, published in the February 2005 issue of the Journal of Neurochemistry, offer tantalizing clues to why drugs like Vioxx and Celebrex, which block COX-2, can ease arthritis but potentially harm the heart and brain.
ProPublica offers an examination of the challenges hospitals face in adopting procedures to address medical errors.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Frank K Hixon, MD 188 Hospital Dr, Suite 101, Fairhope, AL 36532-2043 Ph: (251) 928-0300 | Frank K Hixon, MD 188 Hospital Dr, Suite 101, Fairhope, AL 36532-2043 Ph: (251) 928-0300 |
News Archive
Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.
Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured venture capital investment of A$12 million from GBS Venture Partners Limited, Brandon Capital Partners and Uniseed to fund the development of its pain management drug, EMA401.
A team of cardiovascular researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, Sanford-Burnham Medical Research Institute, and University of California, San Diego have identified a small, but powerful, new player in the onset and progression of heart failure.
Laboratory studies at Johns Hopkins have revealed that certain products of the enzymes COX-1 and COX-2 can both protect and damage the brain. The findings, published in the February 2005 issue of the Journal of Neurochemistry, offer tantalizing clues to why drugs like Vioxx and Celebrex, which block COX-2, can ease arthritis but potentially harm the heart and brain.
ProPublica offers an examination of the challenges hospitals face in adopting procedures to address medical errors.
› Verified 4 days ago
Gustavo Adolfo Diaz, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 411 N Section St Ste 5, Fairhope, AL 36532 Phone: 251-517-5050 Fax: 251-517-5049 | |
Dr. Keith A Kowal, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 20308 Beecher St, Fairhope, AL 36532 Phone: 404-432-2391 | |
William B. Norris, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 188 Hospital Dr, Suite 101, Fairhope, AL 36532 Phone: 251-928-0300 Fax: 251-990-1898 |